Epigenetic Changes Could Signal Increased Cancer Risk
The scientists found that allele-specific methylation was between 5- and 9-fold higher in cancer samples than in those taken from healthy controls—finding such methylation at 15,112 sites around the genome. Of these, 1838 were near sites that had already been linked to disease susceptibility.
![Researchers at The University of Texas MD Anderson Cancer Center have found that a rare resistance mutation first thought to appear in melanoma (pictured) following treatment with a targeted therapy has instead turned out to be hiding in the tumor all along. [Definiens]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1519-100x70.jpeg "Single-Cell Sequencing Uncovers Genetic Roots of Cancer Tumor Diversity")
Epigenetic Changes Could Signal Increased Cancer Risk
The scientists found that allele-specific methylation was between 5- and 9-fold higher in cancer samples than in those taken from healthy controls—finding such methylation at 15,112 sites around the genome. Of these, 1838 were near sites that had already been linked to disease susceptibility.
Pfizer, BioNTech COVID-19 Vaccine Construct Shows Promising Phase I/II Data
The companies said the preliminary data, plus additional preclinical and clinical data now being generated, will help them determine a dose level and select among multiple vaccine candidates for a global Phase IIb/III safety and efficacy trial.
Remote Screening Test for Ovarian Cancer Receives Study Validation
Between 2016 and 2020, a clinical trial engaged nearly 4,000 women from all 50 US states with the intention to validate different combinations of remote genetic counseling—the first large, randomized study of its kind to attempt to do so for cancer risk.
NIH Consortium to Study Molecular Effects of Exercise
The National Institutes of Health-funded Molecular Transducers of Physical Activity Consortium (MoTrPAC) plans to measure molecular changes in healthy adults and children before, during, and after exercise, based on biospecimens provided by the volunteer participants.
CAR-T Cell Therapy for Glioblastoma Shows Early Promise
The reported study data have led to the formation of a new start-up brain cancer immunotherapy company, Empirica Therapeutics, which aims to start clinical trials of the CD133-targeting CAR-T-cell therapy in recurrent glioblastoma patients by 2022.
New Research Shows Why ApoE4 Increases Alzheimer’s Disease Risk
The researchers found that the lipid composition was healthy in the brain of mice with ApoE3 with sufficient amounts of unsaturated fatty acids and endocannabinoids. But when compared to the brain cells of E3, the E4 mice did not receive enough lipids.
Triple negative breast cancer might not actually be ‘breast cancer’
The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
New Research Details How Toxic Substance Exposure Can Cause Cancer
Scientists from the German Cancer Research Center and the Universities of Cambridge and Edinburgh have tracked the impact of the DNA-damaging chemical diethylnitrosamine to better understand how chemicals cause mutations in our cells’ DNA.
SARS-CoV-2 Lineages in Northern California Arrived from Many Areas
It appears no one virus lineage was predominant in northern California, suggesting that transmission between communities was limited. Instead, virus introductions to the state were likely from people traveling from outside the studied counties and the state.
CRISPR Comes of Age—As a Diagnostic
Hailed for its gene editing power, Sherlock Bioscience’s COVID-19 diagnostic is the first CRISPR technology to gain FDA approval.Hailed for its gene editing power, Sherlock Bioscience’s COVID-19 diagnostic is the first CRISPR technology to gain FDA approval.
Five COVID-19 Test Developers to Watch
The coronavirus pandemic compels diagnostics companies to bring new assays, technologies to market.
’Omics in Translation
Proteomics and metabolomics may lag behind genomics in providing clinically actionable insights today, but the future is bright.
Six Precision Medicine Companies Making Their Mark in 2020
This year’s list of innovative companies have all found, or developed, technology solutions that have allowed them to become innovators in their niche.
Keeping up with the Genomes
Molecular diagnostics providers seek ways to maintain services in a world consumed by COVID-19.
Latest by Topic
![Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). [Source: Eraxion/Getty]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1893-218x150.jpeg "Thermo Fisher Inks NSCLC CDx Deal with Daiichi Sankyo")
